Overbought Stocks
URGN appears in our Overbought Stocks screen, meaning it has experienced strong recent gains and may be trading at extended levels that could lead to short-term consolidation or pullback.
UROGEN PHARMA LTD (URGN) Stock Price & Overview
NASDAQ:URGN • IL0011407140
Current stock price
26.06 USD
+1.03 (+4.12%)
At close:
26.06 USD
0 (0%)
After Hours:
The current stock price of URGN is 26.06 USD. Today URGN is up by 4.12%. In the past month the price increased by 44.68%. In the past year, price increased by 153.6%.
URGN Key Statistics
52-Week Range3.42 - 30
Current URGN stock price positioned within its 52-week range.
1-Month Range16.5 - 25.86
Current URGN stock price positioned within its 1-month range.
- Market Cap
- 1.269B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.20
- Dividend Yield
- N/A
URGN Stock Performance
Today
+4.12%
1 Week
+17.95%
1 Month
+44.68%
3 Months
+25.15%
Longer-term
6 Months +31.95%
1 Year +153.60%
2 Years +81.11%
3 Years +115.96%
5 Years +28.69%
10 Years N/A
URGN Stock Chart
URGN Stock Screens
URGN currently appears in the following ChartMill screener lists.
URGN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to URGN. When comparing the yearly performance of all stocks, URGN is one of the better performing stocks in the market, outperforming 95.38% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
URGN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to URGN. URGN has a bad profitability rating. Also its financial health evaluation is rather negative.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
URGN Earnings
On March 2, 2026 URGN reported an EPS of -0.54 and a revenue of 37.84M. The company missed EPS expectations (-5.36% surprise) and missed revenue expectations (-7.08% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateMar 2, 2026
PeriodQ4 / 2025
EPS Reported-$0.54
Revenue Reported37.837M
EPS Surprise -5.36%
Revenue Surprise -7.08%
URGN Forecast & Estimates
14 analysts have analysed URGN and the average price target is 36.34 USD. This implies a price increase of 39.44% is expected in the next year compared to the current price of 26.06.
For the next year, analysts expect an EPS growth of 62.75% and a revenue growth 120.41% for URGN
Analysts
Analysts84.29
Price Target36.34 (39.45%)
EPS Next Y62.75%
Revenue Next Year120.41%
URGN Groups
Sector & Classification
URGN Financial Highlights
Over the last trailing twelve months URGN reported a non-GAAP Earnings per Share(EPS) of -3.2. The EPS increased by 0.93% compared to the year before.
Income Statements
Revenue(TTM)109.79M
Net Income(TTM)-153.49M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -76.57% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%32.5%
Sales Q2Q%54.03%
EPS 1Y (TTM)0.93%
Revenue 1Y (TTM)21.45%
URGN Ownership
Ownership
Inst Owners91.87%
Shares48.68M
Float45.98M
Ins Owners2.02%
Short Float %18.16%
Short Ratio10.56
URGN Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.52 | 362.808B | ||
| AMGN | AMGEN INC | 15.15 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 15.03 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.47 | 111.051B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 79.011B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.5 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.79 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.64 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About URGN
Company Profile
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Company Info
IPO: 2017-05-04
UROGEN PHARMA LTD
9 Ha'ta'asiya St
Ra'anana 08540 IL
CEO: Elizabeth Barrett
Employees: 291
Phone: 97297707601
UROGEN PHARMA LTD / URGN FAQ
What does URGN do?
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Can you provide the latest stock price for UROGEN PHARMA LTD?
The current stock price of URGN is 26.06 USD. The price increased by 4.12% in the last trading session.
Does URGN stock pay dividends?
URGN does not pay a dividend.
How is the ChartMill rating for UROGEN PHARMA LTD?
URGN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy URGN stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on URGN.
Can you provide the growth outlook for UROGEN PHARMA LTD?
The Revenue of UROGEN PHARMA LTD (URGN) is expected to grow by 120.41% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the next earnings date for URGN stock?
UROGEN PHARMA LTD (URGN) will report earnings on 2026-05-07.